Gonadorelin: Evidence, Mechanism, Dosing & Legal Status

Gonadorelin is the exact ten-amino-acid hypothalamic decapeptide that drives the pituitary to release LH and FSH — native gonadotropin-releasing hormone, also called LHRH.12 It was once sold for human use as Factrel (a diagnostic) and Lutrepulse (a pump therapy), and it has re-entered the spotlight as a compounded TRT adjunct. This monograph separates what is proven from what is merely popular.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. Gonadorelin is a prescription/diagnostic agent and is prohibited in male sport. Dosing figures are reported strictly as seen in the published literature and historical labeling for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is gonadorelin and how does it work?

Gonadorelin is a decapeptide identical in sequence to endogenous GnRH/LHRH (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2; molecular formula C55H75N17O13, MW approximately 1182 free base), the proteolytic product of a 92-amino-acid precursor, marketed as the hydrochloride (Factrel) or acetate (Lutrepulse) salt.15 It binds the GnRH receptor (GnRHR), a seven-transmembrane Gq/11-coupled GPCR on anterior-pituitary gonadotroph cells; binding triggers IP3-mediated calcium release plus voltage-gated calcium influx, driving synthesis and secretion of LH and FSH, which in turn drive gonadal steroidogenesis and gametogenesis.23

The defining pharmacology is pulsatility — an agonist that becomes a suppressant depending on how you deliver it. Endogenous GnRH is secreted in pulses roughly every 60 to 120 minutes; delivered in matching pulses, gonadorelin stimulates physiologic LH and FSH.2 Delivered continuously, or as a long-acting super-agonist analogue such as leuprolide, the same receptor agonism causes GnRHR downregulation and desensitization, collapsing LH and FSH after an initial flare — chemical castration.43 Pulse frequency also tunes the LH:FSH ratio (faster favors LH, slower favors FSH).3 Reinforcing this, gonadorelin has an extremely short plasma half-life — on the order of 2 to 4 minutes by some sources — being rapidly hydrolysed to inactive fragments and renally cleared; that rapid clearance is functional, not incidental, because it permits a clean pulse and prevents continuous-exposure desensitization, which is why sustained therapy historically required an infusion pump.67

What is the evidence by indication?

Gonadorelin's evidence is unusually stratified: a validated diagnostic, two genuinely effective pump therapies, and one popular-but-unproven extrapolation. The table summarizes where each use sits.

The diagnostic use is the original FDA indication. A single 100-mcg bolus with LH/FSH sampling at 0, 30, 60 and 120 minutes distinguishes hypothalamic from pituitary causes of hypogonadism and helps separate constitutional delay of puberty from hypogonadotropic hypogonadism.111 Performance is well characterized: a 30-minute peak LH of at least 5 IU/L distinguished central from peripheral precocious puberty with sensitivity 99 percent and specificity 100 percent, while in males a peak LH below about 9.74 IU/L identified hypogonadotropic hypogonadism with sensitivity around 74 to 80 percent and specificity 86 to 91 percent.1211 Here efficacy means diagnostic accuracy, not treatment.

The two pump therapies are where gonadorelin treats. In a pivotal study of 109 women with hypothalamic amenorrhea, pulsatile gonadorelin produced ovulation in 91 to 96 percent of patients, and a 25-year cohort reported a 96 percent ovulation rate per cycle with 75 percent monofollicular ovulation and low multiple-gestation rates — positioning the pump as safer and more physiologic than injectable gonadotropins.89 In male congenital hypogonadotropic hypogonadism, a multicentre prospective self-controlled trial of 28 men showed LH rising from 0.20 to 5.96 IU/L and FSH from 0.53 to 5.51 IU/L by six months, and a systematic review and meta-analysis (7 studies, 420 patients) found pulsatile GnRH associated with earlier spermatogenesis (weighted mean difference -5.30 months) and larger testicular volume versus combined gonadotropins, with no significant difference in overall spermatogenesis rate.1314 Both indications are real human efficacy against an active comparator — graded B because placebo-RCTs are impractical in anovulatory or azoospermic populations.

That brings us to the TRT adjunct, the weakest-evidenced and most marketed use. The rationale is sound: exogenous testosterone suppresses LH and FSH, dropping intratesticular testosterone by up to roughly 94 percent and impairing spermatogenesis, and gonadorelin should in principle restore pulsatile LH and FSH — and uniquely, unlike hCG, also drives FSH.2829 But every controlled gonadorelin study is for pump-delivered pulsatile therapy in diagnosed hypogonadotropic conditions, not for intermittent subcutaneous injections layered on top of TRT, and in a deeply suppressed axis non-pulsatile dosing may not reliably maintain intratesticular testosterone — while excessive or continuous dosing can desensitize the axis, the opposite of the goal.2830 Grade D: plausible, widely practiced, unproven.

What doses appear in the literature?

Reported strictly as information, not a protocol. For the diagnostic stimulation test, the literature and historical labeling describe a single 100-mcg subcutaneous or intravenous bolus in adults (60 mcg/m2, max 100 mcg, in children) with LH/FSH drawn at 0, 30, 60 and 120 minutes.111 For the ovulation-induction pump (Lutrepulse), a typical starting regimen was about 5 mcg every 90 minutes via subcutaneous or intravenous infusion pump, with response usually within two to three weeks.831 For male CHH the pump delivers pulses roughly every 90 to 120 minutes, titrated to LH, FSH and testosterone over months.13 The TRT-adjunct subcutaneous dosing seen in compounding and telehealth practice varies widely (commonly small microgram doses two to three times weekly or more frequently) — this is not derived from controlled trials, and high or continuous dosing risks axis desensitization. The official ClinicalTrials.gov registry of GnRH studies can be browsed at clinicaltrials.gov for the underlying pump trials.4

How safe is gonadorelin?

Most adverse effects are mild: injection-site reactions, headache, light-headedness, flushing, nausea and abdominal discomfort, with local or generalized skin rash possible during chronic subcutaneous use.161 The serious risks are rare but real. Hypersensitivity and anaphylaxis — bronchospasm, tachycardia, urticaria, hypotension, syncope — have been reported especially after repeated or multiple-dose administration; a documented case described a man on ten weeks of pulsatile subcutaneous GnRH who developed near-immediate dizziness, hypotension and loss of consciousness after an intravenous dose, so first intravenous exposure should occur where anaphylaxis can be managed, and cross-reactivity across analogues warrants skin testing before switching.1517 Pituitary apoplexy — hemorrhage or infarction of a pre-existing adenoma — is a rare class risk.18 In ovulation induction, multiple pregnancy runs around 12 percent in pump series with rare OHSS.8 Contraindications include known hypersensitivity to GnRH/LHRH or analogues, pituitary adenoma, and conditions aggravated by rising sex steroids; gonadotropin responses are also altered by spironolactone, oral contraceptives and digoxin, so the diagnostic test should run off interfering drugs.1

What is the FDA and WADA status in 2026?

Gonadorelin was FDA-approved for human use — Factrel for HPG-axis diagnostic testing and Lutrepulse for ovulation induction — but both were discontinued for commercial or business reasons, not safety or efficacy.128 As of 2026 no FDA-approved human gonadorelin product is commercially marketed in the United States; the only active approved Factrel is a veterinary product for cattle, explicitly not for human use.1 Crucially, gonadorelin acetate is a Category 1 bulk substance on the FDA's interim 503A and 503B compounding lists, meaning the FDA does not intend to take action against compounders using it while evaluation continues; the January 2025 final interim guidance finalized the earlier draft and retained permissible Category 1 substances.1921 Gonadorelin's Category 1 standing contrasts with the Category 2 restriction of several growth-hormone-secretagogue peptides, and an FDA Pharmacy Compounding Advisory Committee meeting was scheduled for July 23-24, 2026 to review additional peptides.2223 Net practical position: gonadorelin can be legally compounded by licensed 503A/503B pharmacies and prescribed via telehealth with a valid prescription, while gray-market 'research-chemical' gonadorelin sold without a prescription is not legitimate for human use.2432

For sport the rule is sex-specific. Gonadorelin and its agonist analogues are prohibited at all times in males under S2.2.1 (testosterone-stimulating peptides) of the 2026 WADA Prohibited List because they raise endogenous testosterone; GnRH analogues have been listed since January 1, 2016, and metabolites are likewise prohibited.2526 The same substance is not prohibited in female athletes, and a male athlete with a legitimate medical need would require a Therapeutic Use Exemption.27

Bottom line. Gonadorelin is the real thing — native GnRH — and its value is inseparable from the pulse. Treat the diagnostic test and the pulsatile pump therapies as evidence-backed (B, with the diagnostic effectively A as a test), and treat the intermittent-SC TRT-adjunct use as a reasonable but unproven extrapolation (D), where hCG and enclomiphene currently carry the deeper evidence base. Legally it is unmarketed yet compoundable (Category 1) and telehealth-prescribable, and prohibited in male athletes. Regulatory facts are current as of June 2026; the July 23-24, 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date.